SAN DIEGO--(BUSINESS WIRE)--
Retrophin, Inc. (NASDAQ:RTRX) today announced that at a Special Meeting
of Stockholders held earlier today, the Company's stockholders voted to
approve a proposal ratifying the prior issuance of stock options to
purchase 1,928,000 shares of common stock and 230,000 restricted shares
of common stock granted to employees between February 24, 2014 and
August 18, 2014. Approximately 99.3% of votes present in person or by
proxy at the meeting were cast in favor of the proposal.
The proposal described above was submitted for approval at the Special
Meeting of Stockholders in order for Retrophin to regain compliance with
Nasdaq Listing Rule 5635(c). Following the approval of the proposal at
the Special Meeting of Stockholders, Retrophin believes that it has
satisfied its obligations under the plan of compliance previously
approved by Nasdaq.
About Retrophin
Retrophin is a pharmaceutical company focused on the development,
acquisition and commercialization of drugs for the treatment of serious,
catastrophic or rare diseases for which there are currently no viable
options for patients. Retrophin's approved products include Chenodal®,
Thiola® and Vecamyl®, and its pipeline includes compounds for several
catastrophic diseases, including focal segmental glomerulosclerosis
(FSGS), pantothenate kinase-associated neurodegeneration (PKAN),
schizophrenia, infantile spasms, nephrotic syndrome and others. For
additional information, please visit www.retrophin.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and commercialization of
pharmaceutical products. Without limiting the foregoing, these
statements are often identified by the words "may", "might", "believes",
"thinks", "anticipates", "plans", "expects", "intends" or similar
expressions. No forward-looking statement can be guaranteed. You are
cautioned not to place undue reliance on these forward-looking
statements as there are important factors that could cause actual
results to differ materially from those in forward-looking statements,
many of which are beyond our control. Retrophin undertakes no obligation
to publicly update forward-looking statements, whether as a result of
new information, future events, or otherwise. Investors are referred to
the full discussion of risks and uncertainties as included in
Retrophin's filings with the Securities and Exchange Commission.
Retrophin, Inc.
Chris Cline, CFA, 646-564-3680
Manager,
Investor Relations
IR@retrophin.com
Source: Retrophin, Inc.
News Provided by Acquire Media